Fluicell AB - Asset Resilience Ratio

Latest as of September 2025: 6.04%

Fluicell AB (FLUI) has an Asset Resilience Ratio of 6.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Fluicell AB to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr990.00K
≈ $106.54K USD Cash + Short-term Investments

Total Assets

Skr16.38 Million
≈ $1.76 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Fluicell AB's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Fluicell AB to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Fluicell AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Fluicell AB.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr990.00K 6.04%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr990.00K 6.04%

Asset Resilience Insights

  • Limited Liquidity: Fluicell AB maintains only 6.04% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Fluicell AB Industry Peers by Asset Resilience Ratio

Compare Fluicell AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Fluicell AB (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Fluicell AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 62.43% Skr15.92 Million
≈ $1.71 Million
Skr25.51 Million
≈ $2.75 Million
+32.85pp
2023-12-31 29.58% Skr2.76 Million
≈ $297.34K
Skr9.34 Million
≈ $1.01 Million
-47.41pp
2022-12-31 76.99% Skr24.46 Million
≈ $2.63 Million
Skr31.77 Million
≈ $3.42 Million
+0.29pp
2021-12-31 76.70% Skr20.69 Million
≈ $2.23 Million
Skr26.98 Million
≈ $2.90 Million
+0.98pp
2020-12-31 75.71% Skr18.80 Million
≈ $2.02 Million
Skr24.83 Million
≈ $2.67 Million
+33.40pp
2019-12-31 42.32% Skr8.44 Million
≈ $907.96K
Skr19.94 Million
≈ $2.15 Million
-43.27pp
2018-12-31 85.59% Skr22.23 Million
≈ $2.39 Million
Skr25.97 Million
≈ $2.80 Million
+17.69pp
2017-12-31 67.91% Skr7.83 Million
≈ $842.96K
Skr11.54 Million
≈ $1.24 Million
+28.30pp
2016-12-31 39.60% Skr1.10 Million
≈ $118.27K
Skr2.77 Million
≈ $298.63K
--
pp = percentage points

About Fluicell AB

ST:FLUI Sweden Biotechnology
Market Cap
$4.69 Million
Skr43.55 Million SEK
Market Cap Rank
#28698 Global
#651 in Sweden
Share Price
Skr31.70
Change (1 day)
+2.26%
52-Week Range
Skr7.70 - Skr57.20
All Time High
Skr188.78
About

Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of mu… Read more